SecBot SecBot
SC 13G/A ·Filed Nov 13, 2026

RARE

Ultragenyx Pharmaceutical Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3d 19h ago SEC0001167557-26-000260
Passive stake amendment
Actionable Insight • Neutral

AQR's stake is minimal and passive; no material impact on the stock. Monitor for any future 13D conversion if the position grows, but this filing is routine.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$16.08
T+0 close · Nov 13, 2026 · via day close
Latest settled
−1.12%
T+1 · $15.90
Vs SPY
+0.79%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $16.08entry
  2. T+1 · 21h ago −1.12%α +0.79% · $15.90
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AQR Capital Management filed an amended Schedule 13G disclosing a 0.64% passive stake in Ultragenyx Pharmaceutical as of September 30, 2026, down from a prior position. This is a routine passive filing by a quantitative asset manager, indicating no intent to influence control.

Key Financial Metrics

Stake
0.64%
Stake Value
$10.8M
Investor
AQR Capital Management LLC
Investor Type
hedge fund

Key Facts

  • AQR Capital Management holds 633,393 shares of Ultragenyx common stock, representing 0.64% of shares outstanding as of September 30, 2026.
  • The filing is an amendment to Schedule 13G, indicating a passive investment intent under Rule 13d-1(b).
  • AQR Capital Management Holdings, LLC is the parent entity, also filing jointly.

Financial Impact

Stake valued at approximately $10.8 million based on market cap of $1.7B and 0.64% ownership.

ownership_percentage

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
59% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001167557-26-000260
Document: 0001167557-26-000260-index.html0001167557-26-000260
Document: 0001167557-26-000260.txt0001167557-26-000260

Track record

22 reports on RARE

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Viewing Entry $16.08 Now $15.90 −1.12% settles Nov 20
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
  3. Nov 3, 202613d ago 8-K Mixed 6/10 No price data
  4. Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
  5. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
  6. Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
  7. Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
  8. Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
  9. Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
  10. Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 5h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026